Skip to main content

Muscular Dystrophy and cannabis in Maine

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Up to 2.5 oz of harvest…
POSSESSION
$0/yr
STATE FEE
1–14 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Maine statute and program

The Maine Medical Use of Marijuana Program is the operating authority for Maine patient certification. The authoritative legal text is: Maine Revised Statutes Title 28-B: Adult Use Cannabis. The program portal is at Maine Medical Use of Marijuana Program.

What the evidence says about cannabis and Muscular Dystrophy

Muscular dystrophy refers to a group of more than 30 inherited genetic disorders characterized by progressive muscle weakness and degeneration caused by mutations in genes encoding proteins that maintain muscle-fiber integrity. The major clinical subtypes include:

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Muscular Dystrophy page.

How to qualify in Maine

The Maine Medical Use of Marijuana Program requires the following registration steps for a Muscular Dystrophy patient (or any qualifying diagnosis):

  1. Get a written certification from a Maine medical provider. Any Maine-licensed physician, certified nurse practitioner, or physician assistant authorized to prescribe controlled substances may issue a written certification stating that the patient has been diagnosed and that medical cannabis may provide therapeutic or palliative benefit. Maine moved to a provider-discretion program in 2018 (LD 1539) — the state no longer maintains an enumerated qualifying-condition list.
  2. Keep the certification with your government-issued ID. Maine eliminated the mandatory state patient registry for adult patients in 2018. Adult patients are not required to enroll with the Office of Cannabis Policy; the provider-issued written certification combined with a valid government ID is sufficient legal documentation at dispensaries and during any law-enforcement encounter. Minors must enroll in the registry.
  3. Optional registry enrollment (zero state fee for adult patients). Patients may voluntarily enroll in the Maine Office of Cannabis Policy patient registry to receive a physical Maine Medical Use of Marijuana Program identification card. There is no state fee for adult patient enrollment. Caregiver registration is separate and carries an annual fee under OCP rules.
  4. Purchase from licensed Maine medical caregivers or dispensaries. With a current written certification, patients may purchase from any licensed Maine medical caregiver storefront or registered dispensary. Maine honors out-of-state medical cards from any state under its reciprocity provision; out-of-state patients may purchase medical cannabis in Maine using their home-state registration for up to 30 days. Adult-use retail also exists statewide for purchasers 21 and older.
State registration fee
$0
Physician visit (typical)
$150–$300
Certification to card
1–14 days
Out-of-state patients
Eligible
Minors
Eligible with caregiver

For full Maine registration steps, fees, and reciprocity rules, see the Maine cannabis-laws page.

ICD-10 code

A certifying physician documenting Muscular Dystrophy for the Maine medical cannabis program will typically record ICD-10 G71.0 or SNOMED-CT 76670001 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Maine list Muscular Dystrophy as a qualifying condition for medical cannabis?

No. Maine's qualifying-condition list does not currently include Muscular Dystrophy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Muscular Dystrophy in Maine have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Maine program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Maine medical marijuana card for Muscular Dystrophy?

Because Maine does not currently list Muscular Dystrophy as a qualifying condition, a card for Muscular Dystrophy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Maine who is registered with Maine Medical Use of Marijuana Program and willing to evaluate Muscular Dystrophy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Maine honors out-of-state medical cards under its reciprocity rules — uncommon, and worth verifying before relying on it. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the Maine Medical Use of Marijuana Program site at https://www.maine.gov/dafs/omp/medical-use; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Muscular Dystrophy?

For Muscular Dystrophy, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Muscular Dystrophy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Muscular Dystrophy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Muscular Dystrophy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Muscular Dystrophy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Maine Revised Statutes Title 28-B: Adult Use Cannabisaccessed May 16, 2026
  2. Maine Revised Statutes Title 22 Chapter 558-C: Medical Use of Cannabisaccessed May 16, 2026
  3. Maine Office of Cannabis Policyaccessed May 16, 2026
  4. Wikipedia: Cannabis in Maineaccessed May 16, 2026
  5. NIH National Institute of Neurological Disorders and Stroke: Muscular Dystrophyaccessed May 18, 2026
  6. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea.”

  7. Muscular Dystrophy Association: About Neuromuscular Diseasesaccessed May 18, 2026
  8. MedlinePlus: Muscular dystrophyaccessed May 18, 2026
  9. FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 18, 2026